Headquartered in Deerfield, IL Fiscal year ends December NYSE: BAX baxter.com
Baxter International Inc. is a global medtech company that provides essential healthcare solutions across hospitals, physician offices, and other care settings. The company operates through two reportable segments: Medical Products & Therapies (encompassing sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies, surgical hemostat and sealant products, specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding) and Healthcare Systems & Technologies (encompassing connected care solutions and collaboration tools including smart bed systems, patient monitoring systems, diagnostic technologies, respiratory health devices, and advanced surgical equipment such as operating room integration technologies and precision positioning devices). Baxter divested its former Kidney Care business and continues to supply products to the acquirer, Vantive Health, under a manufacturing and supply agreement. The company employs approximately 37,500 people and trades on the NYSE under the ticker BAX. Updated
AbbVie and Baxter both flashed the same bullish technical signal this month, but one golden cross signals genuine momentum while the other masks a fundamentally broken business. Knowing which is which could…
These three stocks from the Goldman Sachs U.S. Conviction List come with dependable dividends, making them ideal for investors interested in passive income and total return.
These four Goldman Sachs U.S. Conviction List stock picks come with dependable dividends for those seeking passive income.
Bed Bath & Beyond has finally answered the question of when it would file for bankruptcy, and Chile is sticking its nose into the lithium business.
A tech recovery on Monday does not appear to be lasting into Tuesday.
The CES show closed on Sunday, Alibaba co-founder Jack Ma is walking away from control of Ant Group, and Goldman Sachs is getting set to fire about 3,200 employees.
Tuesday's top analyst upgrades and downgrades included AT&T, Baxter International, Centene, Darden Restaurants, Lennar, L3 Harris Technologies, MGM Resorts International, Nvidia and Vertex Pharmaceuticals.
Friday's top analyst upgrades and downgrades included AT&T, Baxter International, Delta Air Lines, DXC Technology, JetBlue Airways, Marriott International, MongoDB, PPL, RingCentral, Snap, Snowflake, Verizon Communications and Western Digital.
Tuesday's top analyst upgrades and downgrades included Accenture, Analog Devices, Apple, Baxter International, Best Buy, Coterra Energy, Emerson Electric, Johnson Controls, Lam Research, Micron Technology, Qualcomm, Silvergate Capital, Tapestry and Walt Disney.
Monday's top analyst upgrades and downgrades included Accenture, Analog Devices, Baxter International, Best Buy, Coinbase Global, Johnson Controls, Lam Research, Micron Technology and Qualcomm.
Thursday’s top analyst upgrades and downgrades included Advanced Micro Devices, Baxter International, Caesars Entertainment, Electronic Arts, Exact Sciences, Gilead Sciences, Intel, JetBlue Airways, Marriott International, Match Group, Microchip Technology, Starbucks and Uber…
Friday's additional top analyst upgrades and downgrades included Altria, Aurora Cannabis, Baxter International, Marathon Oil, Progressive and Shopify.
Top oil exploration and development companies are among those expected to lift the dividends they pay to shareholders this week, making their stocks good total return candidates.
Tuesday's top analyst upgrades and downgrades included Analog Devices, Baxter, BorgWarner, Caesars Entertainment, CarMax, Chevron, Hertz Global, Li Auto, Starbucks, Tesla and Twitter.
Tuesday's top analyst upgrades and downgrades included Advanced Micro Devices, Baxter International, Constellation Energy, CrowdStrike, Datadog, Nutrien, Sandstorm Gold, SentinelOne and Zhihu.
Baxter International Inc. is a global medtech company that provides essential healthcare solutions across hospitals, physician offices, and other care settings.
24/7 Wall St.'s 12-month price target for BAX is $30.44, rated Buy. The Wall Street consensus target is $27.92. BAX price prediction →
